N/A N=154 Behavioral Treatment of Menopausal Insomnia; Sleep and Daytime Outcomes
Menopause
Primary: Diary Based Sleepiness — 5.01; 5.13; 4.87; 4.72 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=56 Insomnia Treatment and Problems (the iTAP Study)
Insomnia · Alcohol; Harmful Use
Primary: Insomnia Severity — 6.86; 10.84; 6.58; 9.32 units on scale, Insomnia Severity Index
N/A N=245 The RESTING Insomnia Study: Randomized Controlled Study on Effectiveness of Stepped-Care Sleep Therapy
Insomnia
Primary: Insomnia Severity Index (ISI) — 15.9; 15.4; 12.7; 11.6 score on a scale — p=0.001
N/A N=45 A High Density EEG Comparison of Sleep Patterns in Insomnia
Primary Insomnia
Primary: EEG Power During Sleep — 1.40; 1.17 μV^2/Hz — p=0.2791
N/A N=28 The Psychoneuroimmunology of Insomnia
Primary Insomnia
Primary: Positive Antibody Response — 7; 7 participants
N/A N=30 Chronic Insomnia and CSF Markers of Dementia
Insomnia Chronic
Primary: CSF Markers Related to Dementia — 4332.1; 4824.0; 393.2; 419.4 picograms per milliliter
N/A N=149 Insomnia Treatment for Women Veterans
Insomnia
Primary: Number of Participants Completing 5 Behavioral Treatment Sessions — 63; 70 Participants — p==.120
N/A N=189 Insomnia Self-Management in Heart Failure
Cardiac Failure · Heart Failure · Congestive Heart Failure
Primary: Change in Insomnia Severity — -6.60; -3.46 score on a scale — p=0.0002
N/A N=21 Reduce Emotional Symptoms of Insomnia With SleepTreatment
Insomnia · Rumination
Primary: Insomnia Severity Index — 16.42; 8.37; 11.72 score on a scale
N/A N=188 Sleep Without Insomnia or The Use of Chronic Hypnotics
Sleep Initiation and Maintenance Disorders
Primary: Rates of Hypnotic Discontinuation — 64; 52 Participants — p=.039
N/A N=28 Hyper-Arousal in Chronic Primary Insomnia
Chronic Insomnia
Primary: Sympathetic Baroreflex Sensitivity (BRS) Unit — -2.1; -4.3 bursts per 100 heart beats per mm Hg
Phase 2 N=125 Evaluation of an Oral Cannabidiol (CBD)-Terpene Formulation on Sleep Physiology in Participants With Insomnia
Insomnia
Primary: Percentage of Time Spent in the Combination of Slow Wave Sleep (SWS) and Rapid Eye Movement (REM) Sleep — 43.0; 41.8 Percentage of total sleep time — p=0.0350
Phase 2 N=34 Chamomile for Chronic Primary Insomnia
Primary Insomnia · Chronic Insomnia
Primary: Change From Baseline of Chamomile Extract on Measures of Sleep at Day 28. — 83.3; 77.5 percentage of time asleep — p=0.21
Phase 3 N=30 Mindfulness Versus Pharmacotherapy for Chronic Insomnia: A Pilot Study
Chronic Insomnia · Primary Insomnia
Primary: Pittsburgh Sleep Quality Index (PSQI) — 7.7; 9.2; 7.0; 8.2 units on a scale
N/A N=32 Metabolomics of Insomnia-Related Hyperarousal
Primary Insomnia
Primary: Number of Metabolites Elevated Relative to the Other Group. — 13; 9 Number of metabolites elevated
Phase 2 N=118 Internet-based Treatment for Chronic Insomnia
Insomnia · Insomnia Disorder
Primary: Sleep Quality — 1.77; 2.18 0-4 scale of sleep quality
N/A N=20 Sleep Loss and Mechanisms of Impaired Glucose Metabolism
Primary Insomnia
Primary: Change in Glucose Tolerance (Kg) in Response to Insulin-modified Intravenous Glucose Tolerance Test — .33; -0.10 %/min, slope of natural log glucose
N/A N=211 Sequenced Therapies for Comorbid and Primary Insomnias
Insomnia Comorbid to Psychiatric Disorder · Primary Insomnia
Primary: Percent of Participants Who Met Remission as Measured by the Insomnia Severity Index — 40.00; 34.94; 37.04; 48.15 percent remitted
Phase 3 N=707 Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia
Primary Insomnia
Primary: Change From Baseline to Day 1&2 in Wake After Sleep Onset (WASO) — 85.0; 86.6; 92.3; 76.5 minutes — p=<0.0001
Phase 4 N=41 Suvorexant and Trauma Related Insomnia
Insomnia · Posttraumatic Stress Disorder
Primary: Change in Insomnia Severity Index Score From Baseline. — 6.8; 8.6 units on a scale — p=<.05
Phase 3 N=126 Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis
Insomnia · End Stage Renal Disease
Primary: Insomnia Severity Index (ISI) Short-term — 12.47; 11.97; 13.05 score on a scale — p=0.6761
Phase 4 N=115 Partial Reinforcement II: Three Approaches to Maintenance Therapy for Chronic Insomnia
Insomnia · Insomnia Chronic
Primary: Treatment Response (Phase 1) — 94 Participants
Phase 4 N=155 CBT-I or Zolpidem/Trazodone for Insomnia
Chronic Insomnia
Primary: Change in Insomnia Symptom Severity — -8.05; -7.82; -10.19 change score on a scale
N/A N=89 Impact of Hyperarousal on Simple and Complex Cognitive Task Performance Among Insomnia Sufferers
Insomnia · Primary Insomnia · Chronic Insomnia
Primary: Number of Incorrect Trials During the Computer-administered Attention-Switching Task Test.Attention-Switching Task Latency Error Rate — 5.11; 3.1 trials
Phase 4 N=103 Reducing Suicidal Ideation Through Insomnia Treatment
Insomnia · Depression · Suicidal Ideation
Primary: Scale for Suicide Ideation Index (SSI) — 4.66; 5.25 units on a scale
Phase 2 N=40 Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes
Insomnia
Primary: Change in Daytime Insomnia Symptoms Scale (DISS) — 65.96; 70.34; 69.22; 72.32 units on a scale
N/A N=27 Multicomponent Behavioral Sleep Intervention for Insomnia in Older Adults With Mild Cognitive Impairment
Mild Cognitive Impairment · Insomnia
Primary: Sleep Latency — 28.51; 47.06 minutes
Phase 2 N=112 Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia
Chronic Primary Insomnia
Primary: Mean Wake Time After Sleep Onset (WASO) — 109.1; 98.7; 90.0; 77.7 minutes — p=0.0018
Phase 3 N=971 Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)
Insomnia Disorder
Primary: Change From Baseline in Subjective Sleep Onset Latency (sSOL) at Month 6 — 64.03; 62.19; 64.97; -16.57 minutes — p=<.0001
Phase 4 N=69 Characteristics of Sleep Patterns in Young Adults With and Without Insomnia
Sleep Disorders
Primary: Change in Pittsburgh Sleep Quality Index — -0.86; -3.15; -3.32 difference score of PSQI total